Follow-The-Filings

Security · featured owners

TSHA

Taysha Gene Therapies Inc. COM SHS Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 1.0%
  • $25M
  • 1 new 2 add

Who owns this now

Largest portfolio weights among featured holders · max 1.0% (Palo Alto Investors) · not free-float ownership

  1. Palo Alto Investors add 1.0%
  2. Farallon Capital Management new 0.07%
  3. Polen Capital Management add 0.03%

holders

sorted by % of portfolio · long equity only · open a manager for their book

history
Palo Alto Investors 2026 Q1 stale 1.0% Add +17.6% 1,391,382 $6M hist
Farallon Capital Management 2026 Q2 0.07% New 0.1% 2,250,000 $15M hist
Polen Capital Management 2026 Q2 0.03% Add +53.0% 489,219 $3M hist

3 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $15.45M $8.33M $9.77M
Gross profit — — —
Gross margin — — —
Net income -$111.57M -$89.3M -$109M
Net margin * -722.1% -1071.6% -1115.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $149.87M $142.13M $324.65M
Total non-current assets * $22.86M $18.23M $18.67M
Total assets $172.73M $160.36M $343.32M
Total current liabilities $36.76M $26.23M $26.55M
Total non-current liabilities * $61.04M $62.61M $69.83M
Total equity $74.94M $71.52M $246.94M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$73.02M -$81.22M -$93.09M
Cash from investing -$7.35M -$363,000 -$604,000
Cash from financing $136.39M $76.68M $274.59M
Net change in cash $56.02M -$4.9M $180.9M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders